Clinical Trials
6 trialsNCT06084689 2025-09-02
EMPIRE
Institut Bergonié
Phase 2 Withdrawn
NCT03982173 2023-01-26
MATILDA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT02201381 2022-07-18
METRICS
Health Clinics Limited
Phase 3 Withdrawn
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT01936961 2017-06-27
I-CREST
Western Regional Medical Center
Phase NA Withdrawn
NCT02567396 2017-04-24
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Withdrawn